Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer (Q38222270)

31 August 2017

Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer (English)

1 reference

31 August 2017

Marcelo Garrido

1

1 reference

31 August 2017

Paula J Fonseca

2

1 reference

31 August 2017

Jose María Vieitez

3

1 reference

31 August 2017

Madalina Frunza

4

1 reference

31 August 2017

Angel J Lacave

5

1 reference

31 August 2017

language of work or name

1 reference

23 June 2014

1 reference

Expert Review of Anticancer Therapy

31 August 2017

1 reference

31 August 2017

14

1 reference

31 August 2017

8

1 reference

31 August 2017

887-900

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

31 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Age-specific trends in incidence of noncardia gastric cancer in US adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Projections of global mortality and burden of disease from 2002 to 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Relation between outcomes and localisation of p-mTOR expression in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.915194

10.1586/14737140.2014.915194

21 January 2018

Identifiers

DOI

1 reference

release_scn3276rufa7vgfswomoa2bnm4

31 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/scn3276rufa7vgfswomoa2bnm4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference